[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models

被引:10
|
作者
Zeng, Ziqing [1 ]
Li, Liqiang [1 ]
Tao, Jinping [1 ]
Liu, Jiayue [1 ]
Li, Hongjun [2 ]
Qian, Xueming [2 ]
Yang, Zhi [1 ]
Zhu, Hua [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, NMPA Key Lab Res & Evaluat Radiopharmaceut, State Key Lab Holist Integrat Management Gastroint, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
[2] Suzhou Transcenta Therapeut Co Ltd, Suzhou 215127, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
CLDN18.2; Lu-177; Tumor radioimmunotherapy; Radionuclide therapy; Gastric cancer; PRETARGETED RADIOIMMUNOTHERAPY; CLAUDIN-18; EXPRESSION; GENE;
D O I
10.1007/s00259-023-06561-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: Gastric cancer (GC), one of the most prevalent and deadliest tumors worldwide, is often diagnosed at an advanced stage with limited treatment options and poor prognosis. The development of a CLDN18.2-targeted radioimmunotherapy probe is a potential treatment option for GC.Methods: The CLDN18.2 antibody TST001 (provided by Transcenta) was conjugated with DOTA and radiolabeled with the radioactive nuclide Lu-177. The specificity and targeting ability were evaluated by cell uptake, imaging and biodistribution experiments. In BGC823(CLDN18.2)/AGS(CLDN18.2) mouse models, the efficacy of [Lu-177]Lu-TST001 against CLDN18.2-expressing tumors was demonstrated, and toxicity was evaluated by H&E staining and blood sample testing.Results: [Lu-177]Lu-TST001 was labeled with an 99.17%+/- 0.32 radiochemical purity, an 18.50 +/- 1.27 MBq/nmol specific activity and a stability of >= 94% after 7 days. It exhibited specific and high tumor uptake in CLDN18.2-positive xenografts of GC mouse models. Survival studies in BGC823(CLDN18.2) and AGS(CLDN18.2) tumor-bearing mouse models indicated that a low dose of 5.55 MBq and a high dose of 11.10 MBq [Lu-177]Lu-TST001 significantly inhibited tumor growth compared to the saline control group, with the 11.1 MBq group showing better therapeutic efficacy. Histological staining with hematoxylin and eosin (H&E) and Ki67 immunohistochemistry of residual tissues confirmed tumor tissue destruction and reduced tumor cell proliferation following treatment. H&E showed that there was no significant short-term toxicity observed in the heart, spleen, stomach or other important organs when treated with a high dose of [Lu-177]Lu-TST001, and no apparent hematotoxicity or liver toxicity was observed.Conclusion: In preclinical studies, [Lu-177]Lu-TST001 demonstrated significant antitumor efficacy with acceptable toxicity. It exhibits strong potential for clinical translation, providing a new promising treatment option for CLDN18.2-overexpressing tumors, including GC.
引用
收藏
页码:1221 / 1232
页数:12
相关论文
共 50 条
  • [21] Clinically Relevant Radioactive Dose Formulation of [177]Lu-Labeled Cetuximab-Fab Fragment for Potential Use in Cancer Theranostics
    Chakravarty, Rubel
    Rohra, Nanda
    Chakraborty, Sudipta
    Jain, Ratnesh
    Sarma, Haladhar Dev
    Dash, Ashutosh
    CHEMISTRYSELECT, 2018, 3 (01): : 242 - 248
  • [22] Synthesis and evaluation of 177Lu-labeled anti-EGFR Fab antibody for lung cancer
    Li, Yuan-Yuan
    Yu, Jia-Yan
    Wang, Tao
    Wang, Jing
    Zhao, Peng
    Yang, Xia
    Wei, Hong-Yuan
    Chen, Yue
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2025, : 2139 - 2149
  • [23] Pretargeted radioimmunotherapy of an anti-CEA bispecific antibody and 177Lu-labeled peptide: a phase I study in patients with advanced colorectal cancer
    Schoffelen, Rafke
    Boerman, Otto C.
    Goldenberg, David M.
    Sharkey, Robert M.
    Herpen, Carla M. L.
    Chang, Chien-Hsing
    Franssen, Gerben M.
    McBride, William J.
    Rossi, Edmund A.
    van der Graaf, Winette T. A.
    Oyen, Wim J. G.
    CANCER RESEARCH, 2012, 72
  • [24] Radiolabeling of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with 177Lu for potential use in radioimmunotherapy
    Lee, So-Young
    Hong, Young-Don
    Pyun, Mi-Sun
    Felipe, Penelope M.
    Choi, Sun-Ju
    APPLIED RADIATION AND ISOTOPES, 2009, 67 (7-8) : 1185 - 1189
  • [25] Therapeutic activity of 177Lu anti-prostate stem cell antigen (PSCA) antibody fragment in a syngeneic mouse model of pancreatic cancer
    Chen, Bao Ying
    Farshbaf, Masoud
    Salazar, Felix
    Chean, Jennifer
    Sherman, Anakim
    Hong, Teresa
    Ahmed, Saad
    Yazaki, Paul
    Adhikarla, Vikram
    Frankel, Paul
    Olafsen, Tove
    Zettlitz, Kirstin
    Wu, Anna
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [26] Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer:: Biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu
    Mohsin, H
    Jia, F
    Sivaguru, G
    Hudson, MJ
    Shelton, TD
    Hoffman, TJ
    Cutler, CS
    Ketring, AR
    Athey, PS
    Simón, J
    Frank, RK
    Jurisson, SS
    Lewis, MR
    BIOCONJUGATE CHEMISTRY, 2006, 17 (02) : 485 - 492
  • [27] Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7:: Evaluation of 177Lu and comparison of its efficacy with that of 90Y and residualizing 131I
    Stein, R
    Govindan, SV
    Chen, S
    Reed, L
    Richel, H
    Griffiths, GL
    Hansen, HJ
    Goldenberg, DM
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (06) : 967 - 974
  • [28] Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model
    Simon, Marina
    Jorgensen, Jesper Tranekjaer
    Khare, Harshvardhan A.
    Christensen, Camilla
    Nielsen, Carsten Haagen
    Kjaer, Andreas
    PHARMACEUTICS, 2022, 14 (06)
  • [29] 64Cu/177Lu labeled anti L1-CAM antibody for a diagnostic and therapeutic convergence radiopharmaceutical in cholangiocarcinoma
    Song, In Ho
    Lee, Tae Sup
    Hong, Hyo Hung
    Kim, Kwang Il
    Lee, Yong Jin
    Kang, Joo Hyun
    Choi, Chang Woon
    Lim, Sang Moo
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [30] Development of optimal Lu-177 labeled monoclonal antibody (7E11) constructs for radioimmunotherapy of prostate cancer.
    Tedesco, J
    Goeckeler, W
    Becker, M
    Frank, K
    Gulyas, G
    Young, SA
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8981S - 8981S